Pacira BioSciences (PCRX) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

2024 achievements and foundation for growth

• Achieved high end of 2024 revenue guidance and established a strong foundation for sustainable growth into 2025 and beyond.

• Secured reimbursement for EXPAREL and iovera under the NOPAIN Act, expanding patient access and overcoming bundled payment barriers, effective January 1.

• Obtained FDA RMAT designation for PCRX-201, with compelling two-year data and three-year data forthcoming.

• Built a robust commercial, medical, and market access organization to drive future growth and innovation.

• Refreshed executive leadership and board, adding diversified talent and experience since 2023.

Strategic vision and 5x30 growth plan

• 5x30 strategy targets treating over 3 million patients by 2030, with double-digit CAGR and five-point gross margin expansion.

• Expanding clinical pipeline with five novel programs and establishing five strategic partnerships by 2030, including ex-US commercialization.

• Focused on musculoskeletal pain and adjacencies, aiming for therapeutic area leadership.

• Three best-in-class products (EXPAREL, ZILRETTA, iovera) positioned for further TAM penetration.

• NOPAIN Act opens reimbursement for 18 million surgical procedures, enhancing product uptake.

Product and pipeline highlights

• EXPAREL benefits from new J code, streamlining billing and reimbursement.

• ZILRETTA is the only FDA-approved extended-release IA injection for OA knee pain, with studies to expand indications to shoulder OA by mid-2026.

• iovera gains $250 additional reimbursement, new 510(k) approval for back pain, and pivotal spasticity study readout expected mid-2026.

• PCRX-201, a first-in-class gene therapy for OA, demonstrated unprecedented two-year pain relief and durability, with over 70% of patients achieving >50% improvement at 16 and 78 weeks.

• PCRX-201 platform has potential to address additional musculoskeletal and non-musculoskeletal diseases.